Fujian Wanchen Biotechnology Co. Ltd Working Capital to Net Assets Ratio
Fujian Wanchen Biotechnology Co. Ltd working capital to net assets ratio. Fujian Wanchen Biotechnology Co. Ltd (300972) has a Working Capital to Net Assets ratio of 98.4% as of March 2026. Working capital of CN¥3.37 Billion (current assets of CN¥9.50 Billion minus current liabilities of CN¥6.13 Billion) is measured against net assets of CN¥3.42 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check Fujian Wanchen Biotechnology Co. Ltd tangible net worth ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Fujian Wanchen Biotechnology Co. Ltd (2019–2025)
Working capital to net assets ratio of Fujian Wanchen Biotechnology Co. Ltd from 2019 to 2025. This chart shows how Fujian Wanchen Biotechnology Co. Ltd's Working Capital to Net Assets ratio has evolved across 7 annual periods from 2019 to 2025. As of March 2026, the ratio stands at 98.4%, reflecting working capital of CN¥3.37 Billion against net assets of CN¥3.42 Billion CNY. See Fujian Wanchen Biotechnology Co. Ltd defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Fujian Wanchen Biotechnology Co. Ltd Working Capital to Net Assets Ratio by Year (2019–2025)
Fujian Wanchen Biotechnology Co. Ltd working capital to net assets ratio by year from 2019 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Fujian Wanchen Biotechnology Co. Ltd from 2019 to 2025, covering 7 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see 300972 asset base.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 102.8% | CN¥2.62 Billion | CN¥2.55 Billion | CN¥8.89 Billion | CN¥6.27 Billion | ▲ +58.8 pp |
| 2024 | 44.0% | CN¥642.52 Million | CN¥1.46 Billion | CN¥5.77 Billion | CN¥5.13 Billion | ▲ +85.8 pp |
| 2023 | -41.8% | CN¥-290.99 Million | CN¥695.81 Million | CN¥2.35 Billion | CN¥2.64 Billion | ▼ -34.0 pp |
| 2022 | -7.9% | CN¥-52.80 Million | CN¥672.36 Million | CN¥278.69 Million | CN¥331.49 Million | ▼ -26.5 pp |
| 2021 | 18.7% | CN¥121.85 Million | CN¥652.71 Million | CN¥302.39 Million | CN¥180.54 Million | ▲ +48.5 pp |
| 2020 | -29.8% | CN¥-119.41 Million | CN¥400.65 Million | CN¥93.13 Million | CN¥212.53 Million | ▲ +8.6 pp |
| 2019 | -38.4% | CN¥-132.55 Million | CN¥344.82 Million | CN¥74.23 Million | CN¥206.78 Million | — |